SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

11276	Companies
250579	Keywords
179215	Articles
136418	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 08/25/2025 at 18:30, 1 year 2 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 08/18/2025 at 18:35, 1 year 2 months ago

Sanofi Reports Total Shares and Voting Rights for July 2025

Voting Rights French Commercial Code Shares 2025 Sanofi
BRIEF

published on 08/18/2025 at 18:35, 1 year 2 months ago

Sanofi publie le nombre total d'actions et de droits de vote pour juillet 2025

Actions Droit De Vote 2025 Sanofi Code De Commerce Français
PRESS RELEASE

published on 08/18/2025 at 18:30, 1 year 2 months ago

Sanofi: Information concerning the total number of voting rights and shares - July 2025
Sanofi discloses total voting rights and issued shares as per French commercial and stock market regulations. Details available on their website

Voting Rights Shares French Regulations Investor Relations Sanofi
BRIEF

published on 08/14/2025 at 07:05, 1 year 2 months ago

Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE

Sanofi EMA Médicament Orphelin Rilzabrutinib Maladie IgG4
BRIEF

published on 08/14/2025 at 07:05, 1 year 2 months ago

Sanofi's rilzabrutinib granted orphan drug designation in the EU

Sanofi EMA Orphan Drug Rilzabrutinib IgG4 Disease
PRESS RELEASE

published on 08/14/2025 at 07:00, 1 year 2 months ago

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4
Sanofi obtient la désignation de médicament orphelin pour le rilzabrutinib dans l'UE contre la maladie liée aux IgG4. Étude de phase 2 positive présentée à l'EULAR 2025

États-Unis Sanofi Médicament Orphelin Rilzabrutinib Maladie IgG4
PRESS RELEASE

published on 08/14/2025 at 07:00, 1 year 2 months ago

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi’s rilzabrutinib granted orphan designation in EU for IgG4-related disease. Positive Phase 2 results presented at EULAR 2025 Congress showcasing efficacy and safety profile

Sanofi Rilzabrutinib Orphan Designation IgG4-related Disease EULAR 2025
PRESS RELEASE

published on 08/11/2025 at 18:30, 1 year 2 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 08/06/2025 at 07:05, 1 year 2 months ago

Sanofi Finalizes Acquisition of Vigil Neuroscience

Acquisition Sanofi Neurology Vigil Neuroscience VG-3927

Accesswire

Published on 11/04/2026 at 23:10, 2 hours 17 minutes ago

Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 2 hours 27 minutes ago

Avino Reports Q3 2026 Financial Results
Published on 11/04/2026 at 23:00, 2 hours 27 minutes ago

Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 3 hours 12 minutes ago

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 3 hours 22 minutes ago

Stabilis Solutions Announces Third Quarter 2026 Results

View all ACCESSWIRE

EQS Group

Published on 11/05/2026 at 00:02, 1 hour 24 minutes ago

EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 5 hours 45 minutes ago

EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 6 hours 2 minutes ago

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 6 hours 44 minutes ago

EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 7 hours 22 minutes ago

Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production

Les Echos

Published on 11/04/2026 at 18:00, 7 hours 27 minutes ago

The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 7 hours 27 minutes ago

L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:45, 7 hours 42 minutes ago

October 2026
Published on 11/04/2026 at 17:45, 7 hours 42 minutes ago

Octobre 2026
Published on 11/04/2026 at 17:44, 7 hours 43 minutes ago

Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026

View all LES ECHOS COMFI WIRE